Small-Caps Are Having Their Best Year in Three Decades — Friday’s Jobs Report Is the Next Test

Friday’s session is dominated by one macro event: the August nonfarm payrolls report (forecast: +55,000, versus July’s -23,000), which will shape Fed rate-hike expectations heading into the central bank’s September meeting. But the more interesting story all week has been the Russell 2000’s historic run — up 21% in 2026 and on pace for its best year in over three decades, dramatically outperforming the S&P 500’s 12.5% gain. Here are 10 stocks to watch tomorrow, September 4, 2026 — all names riding that small-cap wave rather than the usual mega-cap headlines.

1. T1 Energy Inc. (TE) — Closed Near $4.51, Pivoting From Solar Into AI Data Centers

Full Data Snapshot:

The Catalyst: T1 Energy, a U.S. solar module and cell manufacturer, recently received approval to rezone its Giga Arctic manufacturing campus to allow for data center development — a notable strategic pivot for a company originally focused purely on building an integrated domestic solar and battery supply chain. The company also filed a prospectus for convertible notes share resale, adding near-term dilution considerations to the story.

Bull Case: Rezoning a solar manufacturing campus for data center use gives T1 Energy optionality to capture AI infrastructure demand directly, potentially unlocking a second growth avenue beyond its core, currently cyclical solar manufacturing business.

Bear Case: The stock trades 64% below its 52-week high and recently reported a Q2 EPS miss (14-cent loss vs. 10-cent expected), and the convertible notes share resale filing signals potential dilution overhang just as the company pursues a capital-intensive new business line.

Forecast: Watch for concrete data center tenant or partnership announcements tied to the Giga Arctic rezoning; without a signed customer, this remains a speculative option value rather than a confirmed new revenue stream.

2. Artiva Biotherapeutics (ARTV) — Trading Near $9.78, a 300%+ Analyst Target Gap

Full Data Snapshot:

The Catalyst: Artiva Biotherapeutics, a clinical-stage biotech developing NK cell therapies, continues drawing bullish analyst commentary tied to its AlloNK program in refractory rheumatoid arthritis — a first-mover deep B-cell depletion approach for autoimmune disease with pivotal trial plans and FDA discussions set for 2026. Wedbush’s $40 target represents one of the widest gaps between price and target on this list.

Bull Case: Early AlloNK data shows strong efficacy and favorable safety in a high-unmet-need indication, and with multiple firms (Wedbush, Cantor Fitzgerald, Needham) maintaining Buy ratings even after a recent pullback, the setup offers substantial multibagger potential if pivotal trial data confirms the early signal.

Bear Case: A recent -8.43% single-day drop shows the stock remains highly sentiment-sensitive, and clinical-stage biotech carries binary regulatory and trial-execution risk that could invalidate the bull thesis regardless of how compelling the early data looks.

Forecast: Watch for FDA discussion updates and pivotal Phase 3 trial initiation timing; confirmation of a clear registrational pathway would be the single biggest catalyst to close the gap toward Wedbush’s $40 target.

3. Seanergy Maritime Holdings (SHIP) — A Dry Bulk Shipper Near $18, Up 24.8% in Two Weeks

Full Data Snapshot:

The Catalyst: Seanergy Maritime, a dry bulk shipping company operating a Capesize-heavy fleet, has risen sharply in recent weeks, benefiting from firming dry bulk freight rates tied to global iron ore and coal shipping demand. The stock carries buy signals from both short- and long-term moving averages, with the shorter-term average currently above the longer-term one.

Bull Case: A confirmed uptrend backed by both technical moving-average signals and a 3-month MACD buy signal suggests genuine momentum behind the rally, and continued strength in dry bulk freight rates would directly support further earnings growth for Seanergy’s Capesize-heavy fleet.

Bear Case: Technical analysts note the stock sits in the “upper part of a very wide and falling trend” over a longer timeframe, meaning a reaction back toward lower trend support is a real possibility even amid the recent rally — dry bulk shipping rates are also notoriously cyclical and sensitive to Chinese commodity demand.

Forecast: Watch the $17.81 level closely; a break above it would signal a slowing of the longer-term falling trend and potentially the start of a genuine trend reversal, while failure to hold current support levels ($16.59, then $15.09) would validate the more cautious longer-term technical read.

4. Agios Pharmaceuticals (AGIO) — A Hematology Biotech With $52-55 Analyst Targets

Full Data Snapshot:

The Catalyst: Agios reported Q2 revenue of $44.7 million — well above the $26.7 million consensus — driven by robust commercial momentum for mitapivat (PYRUKYND/AQVESME) in thalassemia, alongside FDA acceptance for a sickle cell disease indication. The company holds nearly $1 billion in cash, supporting continued pipeline investment even as some analysts flag regulatory labeling uncertainty (a potential REMS requirement and black box warning) as a near-term overhang.

Bull Case: A revenue beat of this magnitude combined with continued regulatory progress across two rare hematology indications gives Agios genuine, diversifying commercial momentum beyond a single drug launch, with nearly $1 billion in cash providing a long runway.

Bear Case: The company hasn’t provided full detail on REMS or labeling discussions for the sickle cell indication, and the inclusion of a black box warning risk poses a genuine commercial launch risk that could compress the wide gap between the current price and bullish analyst targets.

Forecast: Watch for formal FDA labeling decisions on the sickle cell disease indication; clarity there — positive or negative — will likely be the single biggest catalyst determining whether the stock closes the gap toward Citi and H.C. Wainwright’s $52-55 targets.

5. Shoals Technologies Group (SHLS) — Solar EBOS Maker Near $7, Guidance Raised

Full Data Snapshot:

The Catalyst: Shoals Technologies, which designs and manufactures electrical balance of system (EBOS) solutions for solar and storage projects, raised its full-year 2026 revenue guidance to $600-640 million after posting strong Q2 results, even as analysts flag ongoing margin pressure from increased competition in the solar EBOS market.

Bull Case: A Strong Buy consensus from 29 analysts with a median target implying over 36% upside, combined with raised full-year guidance and 38.6% sequential revenue growth, suggests the company’s execution is outpacing the market’s more cautious margin assumptions.

Bear Case: Multiple analysts have specifically cited “pressure on margins” and “a more competitive market” as reasons for recent target trims even amid the guidance raise, and at 34.9x earnings, the stock isn’t screening as deeply undervalued despite trading well below its 52-week high.

Forecast: Watch for commentary on storage-related revenue contribution specifically; if storage becomes a larger share of the business, it could help offset the margin pressure in the core solar EBOS segment that’s been weighing on recent analyst target revisions.

6. Baldwin Insurance Group (BWIN) — Up 57% in a Month, Testing Analyst Conviction

Full Data Snapshot:

The Catalyst: Baldwin Insurance Group, an insurance brokerage, has staged a remarkable rally after Keefe Bruyette floated the idea that the company “could go private at $26-$30 per share,” with the stock subsequently extending its rally well past that range as BofA and UBS both raised targets to $37 following a Q2 beat, even amid notable catastrophe events (windstorms, flooding in Asia, and the first named Atlantic hurricane of the season).

Bull Case: Multiple analyst target increases immediately following a genuine earnings beat, combined with speculation about a potential go-private transaction, gives Baldwin two distinct catalysts supporting continued upside — either a fundamentals-driven re-rating or takeout premium.

Bear Case: Wells Fargo maintains only a Hold rating, and after a 57% one-month rally, the stock has already priced in significant good news — any disappointment on the go-private speculation or a disappointing catastrophe-loss quarter could trigger a sharp reversal.

Forecast: Watch for any formal confirmation or denial of go-private discussions; that binary catalyst, more than routine earnings commentary, is likely to determine the stock’s next major move given how central it’s become to the current rally.

7. Omnicell Inc. (OMCL) — Pharmacy Automation Play With a Wide Analyst Target Gap

Full Data Snapshot:

The Catalyst: Omnicell, a pharmacy automation and medication management company, posted 15% year-over-year revenue growth in its most recent quarter, returned to full profitability, and raised full-year adjusted EPS guidance by 8.6% — with new product launches including Titan XT and OmniSphere expected to drive continued momentum, alongside the recent hire of a new Chief Pharmacy and Clinical Officer to guide clinical strategy.

Bull Case: A genuine return to profitability combined with an 8.6% guidance raise and new product launches (Titan XT, OmniSphere) gives Omnicell multiple concrete growth drivers, and even the more conservative $54.16 fair value estimate implies meaningful upside from current levels.

Bear Case: Revenue has been flat over the past three years even as the company reports improving profitability, meaning the current rally depends heavily on new product execution translating into actual top-line acceleration rather than just margin improvement.

Forecast: Watch for early sales traction data on Titan XT and OmniSphere in upcoming quarters; those product launches, not the company’s already-improving margin story, will determine whether Omnicell can close the gap toward its higher analyst targets.

8. Freshpet Inc. (FRPT) — A “Pet Humanization” Play With 50% Implied Upside

Full Data Snapshot:

The Catalyst: Freshpet, a fresh pet food maker, has been named among Bank of America and TD Cowen’s top small-cap picks for the second half of 2026, with TD Cowen specifically citing the company’s still-small 2.7% share of the broader pet food market as substantial room for growth tied to the durable “pet humanization” consumer trend.

Bull Case: With such a small current market share in a large, structurally growing category, Freshpet has a long runway for continued expansion if it can keep taking share from legacy pet food brands — the kind of setup that historically supports sustained small-cap outperformance.

Bear Case: Fresh pet food remains a premium-priced category more exposed to consumer discretionary spending pressure than staple pet food brands, and rapid capacity expansion to support growth carries its own execution and margin risk.

Forecast: Watch quarterly same-store and market share data specifically; continued share gains at the current pace would validate TD Cowen’s bull case and support a path toward the $80 target.

9. Everspin Technologies (MRAM) — A Diversified Memory Play at the AI Supply Chain’s Edge

Full Data Snapshot:

The Catalyst: Everspin, a maker of magnetoresistive memory (MRAM) technology, continues trading as one of the more overlooked names in the broader AI and defense-adjacent semiconductor supply chain, offering diversified end-market exposure without the extreme valuation premiums seen in higher-profile AI infrastructure names.

Bull Case: Diversified exposure across industrial, aerospace, defense, and emerging AI/quantum use cases gives Everspin multiple potential growth vectors without concentration risk in any single end market.

Bear Case: Lower analyst coverage and trading liquidity relative to more prominent AI-adjacent names mean positive sector sentiment may take longer to translate into share price appreciation, and the company lacks a single high-visibility catalyst comparable to peers with major hyperscaler contracts.

Forecast: Watch for any new defense or aerospace contract disclosures that could differentiate Everspin’s trajectory from simply tracking broader small-cap semiconductor sentiment.

10. Small-Cap Digital Asset Treasury Basket — A Fresh Crypto Mining Theme Still Under $2 Billion

Full Data Snapshot:

The Catalyst: A cluster of smaller digital asset treasury and cryptocurrency mining companies — with market values still between $279 million and $2 billion despite 2026 gains of 50-300% — continue drawing institutional attention as potential “more room left to run” small-cap crypto plays, according to recent screening from U.S. News.

Bull Case: Companies still trading at relatively modest market caps despite triple-digit percentage gains suggest the broader crypto mining and digital asset treasury theme may not be fully priced in yet, particularly if bitcoin and broader crypto markets continue their 2026 uptrend.

Bear Case: Digital asset treasury companies carry direct balance-sheet exposure to crypto price volatility, and the same triple-digit gains that make this theme attractive also mean much of the near-term good news may already be reflected in current valuations.

Forecast: Watch bitcoin and broader crypto market price action as the primary driver for this basket of names; company-specific mining capacity or treasury disclosure updates would be secondary catalysts layered on top of the crypto market’s overall direction.

Quick-Reference Table: 10 Stocks to Watch on September 4

Sector Sentiment Snapshot and Forecast

Friday’s jobs report is the week’s dominant macro catalyst, but the more durable story underneath it is the extraordinary breadth of the 2026 small-cap rally — the Russell 2000’s 21% year-to-date gain versus the S&P 500’s 12.5% reflects genuine bottom-up earnings strength rather than a narrow handful of winners. T1 Energy and Shoals Technologies both represent the solar/clean-energy supply chain finding new growth angles (AI data centers, raised guidance) even amid sector-wide margin pressure, while Artiva and Agios offer two distinct flavors of biotech binary catalysts with unusually wide gaps to analyst price targets.

Baldwin Insurance’s go-private speculation and Omnicell’s product-driven re-rating round out a list where company-specific catalysts, not broad sector rotation, are driving most of the movement. A soft jobs number Friday could accelerate the small-cap rally further by easing rate-hike fears; a hot number would test whether this year’s historic Russell 2000 outperformance can continue into a potentially bumpier second half.

Follow TNN for daily stock market news and financial and economy news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap and micro-cap securities carry substantially elevated volatility and liquidity risk. Prices, technical levels, and figures cited reflect data available as of September 3, 2026 and are sourced from publicly available market data. Support and resistance levels are technical estimates derived from historical price action and are not guarantees of future performance. Always complete independent due diligence prior to executing equity trades.

About The Author

Kasia Davis

See author's posts